Ionis Pharmaceuticals has announced it will conduct a webcast on July 29 at 8:30 AM Eastern Time to discuss its financial results for the second quarter of 2026 and provide updates on key programs.

The company is a biotechnology firm specializing in RNA-targeted therapies, with a portfolio of commercialized products and a leading research pipeline in areas such as neurology and cardiometabolic diseases. It currently markets six drugs, including TRYNGOLZA (olezarsen), WAINUA (eplontersen), and SPINRAZA (nusinersen) for spinal muscular atrophy.

Key Focus Areas for the Report

The upcoming financial report is drawing significant market attention. In the first quarter of this year, the company's revenue surged 86.4% year-over-year to $246 million, substantially exceeding market expectations of $196 million. Its GAAP net loss per share was $0.56, a marked improvement from the expected loss of $0.85 per share. Driven by this performance, the company raised its full-year 2026 revenue guidance to a range of $875 million to $900 million and projected its year-end cash balance to remain above $1.6 billion. Market consensus anticipates a larger loss for the second quarter, with analysts forecasting an average net loss per share of approximately $1.06. HC Wainwright previously revised its Q2 loss per share estimate down from $0.82 to $1.00.

Investor Attention Points

Investors will be keenly focused on the commercialization progress of two core products, TRYNGOLZA and DAWNZERA, the sustainability of milestone revenue from research and development, and the company's pace toward achieving its goal of cash flow breakeven by 2028. The related financial materials and a replay of the webcast will be made available on the Investor Relations section of the company's website.